Muhammed B. Akinci

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Journal: Cancers

Published: December 10, 2025

Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study.

Journal: Journal of clinical medicine

Published: May 11, 2025

Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.

Journal: International journal of cancer

Published: May 10, 2025

Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer.

Journal: Turkish journal of medical sciences

Published: December 26, 2024

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Journal: Clinical breast cancer

Published: June 29, 2024

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.

Journal: Scientific reports

Published: November 23, 2023

Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

Journal: Journal of cancer research and therapeutics

Published: April 03, 2023

Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.

Journal: Journal of cancer research and therapeutics

Published: December 13, 2022

Can the host immune response against SARS-CoV2 also cause an anticancer effect?

Journal: Medical oncology (Northwood, London, England)

Published: May 26, 2021

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

Journal: Journal of cancer research and clinical oncology

Published: October 03, 2020

Comparison of ıncisional hernia models ın rats: an experimental study.

Journal: Hernia : the journal of hernias and abdominal wall surgery

Published: May 02, 2020

A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint.

Journal: Current medical research and opinion

Published: January 17, 2020

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study.

Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study.

Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.

Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.

Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer.

Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.

Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.

Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.

Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.

Can the host immune response against SARS-CoV2 also cause an anticancer effect?

Can the host immune response against SARS-CoV2 also cause an anticancer effect?

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

Comparison of ıncisional hernia models ın rats: an experimental study.

Comparison of ıncisional hernia models ın rats: an experimental study.

A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint.

A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.